07:40 AM EDT, 10/20/2025 (MT Newswires) -- Glaukos ( GKOS ) said Monday its new drug application for Epioxa, a topical drug therapy for the eye disorder keratoconus, has been approved by the US Food and Drug Administration.

The approval of the drug is based on results from two phase 3 pivotal trials of over 400 patients that achieved their pre-specified primary efficacy endpoints and demonstrated favorable tolerability and safety profiles, the company said.

Glaukos ( GKOS ) said it plans to make Epioxa commercially available in Q1 of 2026.